📰 Karst Peak News
Karst Peak News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Karst Peak. Real-time updates on events, politics, business and more.
December 11, 2023
Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund.
October 11, 2022
Brian Flannery-backed bone fragility imaging tech company CurveBeam AI is tapping investors for $15 million ahead of a 2023 float.
September 7, 2022
Brian Flannery-backed bone fragility imaging tech company StraxCorp is merging with US CT imaging disrupter CurveBeam and kick-starting a pre-IPO raise.
April 3, 2022
Neuren Pharmaceuticals’ share price has almost doubled in six months, but investors think it’s still undervalued as it approaches its first FDA approval.
April 23, 2021
Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are due to report meaningful efficacy and safety endpoints in patients by the end of 2022. The company has a platform technology that has delivered a pipeline of first in class or best in class clinical drugs for inflammatory and fibrotic diseases. The first of these drugs already has an IND approval from the FDA and is currently being trialled in ...
April 15, 2021
Date Time Pharmaxis sells Bronchitol rights in Russia and completes placement Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors. BRONCHITOL was discovered and developed in Australia. Pharmaxis manufactures the medicine at its facility in Sydney. The company has announced the sale of BRONCHITOL distribution rights in Russia to Turkish company GEN İlaç ve Sağlık �...
February 28, 2021
Why the ASX is a rich target for short-selling Mar 1, 2021 â 12.00am Save Share Hedge fund industry pioneer, billionaire, and Tiger Management founder Julian Robertson is credited by Adam Leitzes as the greatest influence on his investing career. Leitzes was hired by Robertson in 2008 after passing an infamous psychological evaluation as part of the interview process to work for the godfather of hedge funds at Tiger. Adam Leitzes of Karst Peak Capital Limited poses for a portrait in the Ce...